Ramucirumab
- Generic Name
- Ramucirumab
- Brand Names
- Cyramza
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 947687-13-0
- Unique Ingredient Identifier
- D99YVK4L0X
- Background
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and down...
- Indication
Ramucirumab is indicated for the treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel for patients who progress after prior fluoropyrimidine- or platinum-containing chemotherapy. It is indicated, in combination with erlotinib, for the first-line treatment of metastatic no...
- Associated Conditions
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Non-Small Cell Lung Cancer, Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Associated Therapies
- -
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Harry H Yoon
- Target Recruit Count
- 58
- Registration Number
- NCT04069273
- Locations
- 🇺🇸
Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Mayo Clinic- Minnesota, Rochester, Minnesota, United States
Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)
- Conditions
- Interventions
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- Masahiro Tsuboi
- Target Recruit Count
- 24
- Registration Number
- NCT04040361
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵Tokyo Medical University Hospita, Shinjuku-Ku, Tokyo, Japan
Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-06-21
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 34
- Registration Number
- NCT03995017
- Locations
- 🇺🇸
University of Kansas Cancer Center - Lee's Summit, Lee's Summit, Missouri, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸KU Cancer Center, Fairway, Kansas, United States
Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-29
- Last Posted Date
- 2019-06-03
- Lead Sponsor
- P. C. Thuss-Patience
- Target Recruit Count
- 59
- Registration Number
- NCT03966118
- Locations
- 🇩🇪
Charité Universitätsmedizin Berlin, Berlin, Germany
Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2019-04-10
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Xiuning Le
- Target Recruit Count
- 160
- Registration Number
- NCT03909334
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Indiana Univesity Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy
- First Posted Date
- 2019-04-04
- Last Posted Date
- 2022-05-26
- Lead Sponsor
- ROGER S KERESZTES MD
- Target Recruit Count
- 3
- Registration Number
- NCT03904108
- Locations
- 🇺🇸
Stony Brook University, Stony Brook, New York, United States
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Toray Industries, Inc
- Target Recruit Count
- 187
- Registration Number
- NCT03872947
- Locations
- 🇺🇸
HOAG Memorial Hospital Presbyterian, Newport, California, United States
🇺🇸Texas Oncology, P.A. Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Northwest Cancer Specialists, Portland, Oregon, United States
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
- Conditions
- Interventions
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 167
- Registration Number
- NCT03798626
- Locations
- 🇺🇸
University of California LA, Los Angeles, California, United States
🇺🇸WA Uni School Of Med, Saint Louis, Missouri, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Korean South West Oncology Group
- Registration Number
- NCT03766607
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of
Study With Paclitaxel +/- Ramucirumab in Patients With Squamous-cell Carcinoma of the Esophagus After Prior Therapy
- Conditions
- Interventions
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2022-12-08
- Target Recruit Count
- 21
- Registration Number
- NCT03762564
- Locations
- 🇩🇪
Institute for Clinical Cancer Research Krankenhaus Nordwest, Frankfurt, Germany
🇩🇪Technische Universität München Klinikum rechts der Isar, Muenchen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.